Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Future Oncology

Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS

6 more authors
17 affiliations
  1. 1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  2. 2Department of Oncology, Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, USA
  3. 3William S. Gibbons Cancer Research Institute, Northwest Georgia Oncology Centers Wellstar, Marietta, GA, USA
  4. 4Hematology/Oncology, West Virginia University Cancer Institute, Morgantown, WV, USA
  5. 5Medical Oncology, Cancer Specialists of North Florida, Fleming Island, FL, USA
  6. 6Oncology & Hematology, Health Partners Institute, Saint Paul, MN, USA
  7. 7Health Partners Institute, Saint Paul, MN, USA
  8. 8Saint Luke’s Cancer Institute, Kansas City, MO, USA
  9. 9Mid-Illinois Hematology & Oncology Associates Ltd, Normal, IL, USA
  10. 10Saint Vincent’s Birmingham, Birmingham, AL, USA
  11. 11Novant Health, Winston-Salem, NC, USA
  12. 12Oncology Medical Group, Pfizer Inc, New York, NY, USA
  13. 13Biostatistics and Medical Writing, ICON Commercialization and Outcomes, ICON Plc., Blue Bell, PA, USA
  14. 14Oncology Clinical Statistics, Pfizer Inc, San Diego, CA, USA
  15. 15Statistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA
  16. 16Global Medical Affairs, Pfizer Inc, San Francisco, CA, USA
  17. 17Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract

Plain Language Summary: What is this summary about?

This summary describes an article published in Cancer Medicine medical journal in April 2026. The article reports the results from a study called POLARIS that looked at treatment outcomes and quality of life for patients with advanced breast cancer (ABC) who also had other medical conditions (also known as comorbidities) in routine clinical practice.

Patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) ABC were included in the study, including those patients with or without comorbidities. The researchers wanted to know if the presence of comorbidities influenced treatment outcomes and quality of life in patients treated with the medicine, palbociclib plus endocrine therapy. Since patients with HR+/HER2- ABC often receive treatment over a long period of time, quality of life is an important outcome measure along with efficacy and safety outcomes.

What are the key takeaways?

This study showed that, in routine clinical practice, patients with HR+/HER2- ABC who had fewer comorbidities tended to experience a longer time until (or before) their cancer got worse than people with more comorbidities; they also tended to live longer overall than people with more comorbidities.

Patients with some blood and lymphatic system disorders tended to live a shorter amount of time before their cancer got worse than those with other medical conditions; they also tended to live a shorter amount of time overall than those with other medical conditions. Presence of comorbidities did not affect patient quality of life during treatment with palbociclib plus endocrine therapy.

What were the main conclusions reported by the researchers?

Together with previous results from POLARIS, the results show that treatment with palbociclib given in routine clinical practice works well for a broad group of patients with HR+/HER2- ABC, including patients with comorbidities. Although, as expected, patients with more comorbidities had poorer survival outcomes, presence of comorbidities does not appear to affect patients’ quality of life during treatment.

Clinical trial number: NCT03280303

Related

  1. Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study
    Chih-Wen Su, Shao-Jing Wang, Yu-Hsiang Shih +9
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Cost-effectiveness of inavolisib plus palbociclib/fulvestrant versus palbociclib/fulvestrant for PIK3CA-mutated advanced breast cancer in China
    Zuojuan Xiang, Xiaojuan Chen, Ling Ma
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefDOAJEurope PMCPMC
  3. Genetic Variation in NR1I2 and Palbociclib Safety and Prognosis in Advanced Breast Cancer: An Exploratory Multicenter Study
    Cristina Arqueros, Marta Andrés, Sònia Servitja +6
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General medicineCrossref
  4. Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
    E. Carola, P. Caillet, C. Falandry +19
    The BreastPeer-reviewedCC BY-NC-ND 4.0Full text1 citedGeneral biologyOncologyHAL
  5. Shared Decision-Making and Decision Support in Advanced Chronic Kidney Disease: A Systematic Review of Models, Treatment Pathways, and Patient-Centered Outcomes
    Awais Naeem, Zulfiqar Ashraf, Sajjad Ali +8
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{tripathy2026treatment,
  title = {{Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS}},
  author = {Debu Tripathy and Joanne L. Blum and Meghan S. Karuturi and Steven McCune and Sobha Kurian and Mehdi M. Moezi and Daniel M. Anderson and Yan Ji and Timothy J. Pluard and John Migas and Shailendra Lakhanpal and Erin Jepsen and Yao Wang and Monica Z. Montelongo and Zhe Zhang and Joseph C. Cappelleri and Eric Gauthier and Gabrielle B. Rocque},
  journal = {Future Oncology},
  year = {2026},
  month = nov,
  doi = {10.1080/14796694.2026.2747581},
  url = {https://doi.org/10.1080/14796694.2026.2747581},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS
AU  - Debu Tripathy
AU  - Joanne L. Blum
AU  - Meghan S. Karuturi
AU  - Steven McCune
AU  - Sobha Kurian
AU  - Mehdi M. Moezi
AU  - Daniel M. Anderson
AU  - Yan Ji
AU  - Timothy J. Pluard
AU  - John Migas
AU  - Shailendra Lakhanpal
AU  - Erin Jepsen
AU  - Yao Wang
AU  - Monica Z. Montelongo
AU  - Zhe Zhang
AU  - Joseph C. Cappelleri
AU  - Eric Gauthier
AU  - Gabrielle B. Rocque
PY  - 2026
DA  - 2026/11/06
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2747581
UR  - https://doi.org/10.1080/14796694.2026.2747581
AB  - Plain Language Summary: What is this summary about?  This summary describes an article published in Cancer Medicine medical journal in April 2026. The article reports the results from a study called POLARIS that looked at treatment outcomes and quality of life for patients with advanced breast cancer (ABC) who also had other medical conditions (also known as comorbidities) in routine clinical practice.  Patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) ABC were included in the study, including those patients with or without comorbidities. The researchers wanted to know if the presence of comorbidities influenced treatment outcomes and quality of life in patients treated with the medicine, palbociclib plus endocrine therapy. Since patients with HR+/HER2- ABC often receive treatment over a long period of time, quality of life is an important outcome measure along with efficacy and safety outcomes.  What are the key takeaways?  This study showed that, in routine clinical practice, patients with HR+/HER2- ABC who had fewer comorbidities tended to experience a longer time until (or before) their cancer got worse than people with more comorbidities; they also tended to live longer overall than people with more comorbidities.  Patients with some blood and lymphatic system disorders tended to live a shorter amount of time before their cancer got worse than those with other medical conditions; they also tended to live a shorter amount of time overall than those with other medical conditions. Presence of comorbidities did not affect patient quality of life during treatment with palbociclib plus endocrine therapy.  What were the main conclusions reported by the researchers?  Together with previous results from POLARIS, the results show that treatment with palbociclib given in routine clinical practice works well for a broad group of patients with HR+/HER2- ABC, including patients with comorbidities. Although, as expected, patients with more comorbidities had poorer survival outcomes, presence of comorbidities does not appear to affect patients’ quality of life during treatment.  Clinical trial number: NCT03280303
SN  - 1479-6694
SN  - 1744-8301
ER  -